Prospective observational records on antithrombotic treatment in patients with atrial fibrillation undergoing coronary angioplasty with stent implantation
| Author/acronym . | Years . | . | Patients (n) . | TAT (%) . | DAT (%) . | DAPT (%) . | DOAC (%) . |
|---|---|---|---|---|---|---|---|
| Saratoff et al.31 | 2002–07 | Monocenter/Germany | 515 | 59 | 0 | 41 | 0 |
| STENTICO32 | 2005–06 | Multicentric/France | 359 | 100 | 0 | 0 | 0 |
| MUSICA33 | 2003–06 | Multicentric/Spain | 405 | 69 | 11 | 20 | 0 |
| AFCAS34 | 2008–10 | Multicentric/Europe | 914 | 74 | 8 | 18 | 0 |
| WARSTENT35 | 2008–10 | Multicentric/Italy | 401 | 85 | 5 | 10 | 0 |
| Sambola et al.36 | 2003–12 | Multicentric/Spain | 585 | 55 | 0 | 45 | 0 |
| Horie et al.37 | 2015–17 | Multicentric/Japan | 285 | 100 | 0 | 0 | 0 |
| CHUM AF STENT38 | 2010–19 | Multicentric/Canada | 561 | 44 | 8 | 47 | 32 |
| GRAPE AF39 | 2017–19 | Multicentric/Greece | 654 | 50 | 49 | 1 | 93 |
| MATADOR-PCI40 | 2018–19 | Multicentric/Italy | 588 | 65 | 9 | 26 | 62 |
| Author/acronym . | Years . | . | Patients (n) . | TAT (%) . | DAT (%) . | DAPT (%) . | DOAC (%) . |
|---|---|---|---|---|---|---|---|
| Saratoff et al.31 | 2002–07 | Monocenter/Germany | 515 | 59 | 0 | 41 | 0 |
| STENTICO32 | 2005–06 | Multicentric/France | 359 | 100 | 0 | 0 | 0 |
| MUSICA33 | 2003–06 | Multicentric/Spain | 405 | 69 | 11 | 20 | 0 |
| AFCAS34 | 2008–10 | Multicentric/Europe | 914 | 74 | 8 | 18 | 0 |
| WARSTENT35 | 2008–10 | Multicentric/Italy | 401 | 85 | 5 | 10 | 0 |
| Sambola et al.36 | 2003–12 | Multicentric/Spain | 585 | 55 | 0 | 45 | 0 |
| Horie et al.37 | 2015–17 | Multicentric/Japan | 285 | 100 | 0 | 0 | 0 |
| CHUM AF STENT38 | 2010–19 | Multicentric/Canada | 561 | 44 | 8 | 47 | 32 |
| GRAPE AF39 | 2017–19 | Multicentric/Greece | 654 | 50 | 49 | 1 | 93 |
| MATADOR-PCI40 | 2018–19 | Multicentric/Italy | 588 | 65 | 9 | 26 | 62 |
DAPT, dual antiplatelet therapy; DAT, dual antithrombotic therapy (anticoagulant + single antiplatelet); DOAC, direct anticoagulants; TAT, triple antithrombotic therapy (anticoagulant + dual antiplatelet therapy).
Prospective observational records on antithrombotic treatment in patients with atrial fibrillation undergoing coronary angioplasty with stent implantation
| Author/acronym . | Years . | . | Patients (n) . | TAT (%) . | DAT (%) . | DAPT (%) . | DOAC (%) . |
|---|---|---|---|---|---|---|---|
| Saratoff et al.31 | 2002–07 | Monocenter/Germany | 515 | 59 | 0 | 41 | 0 |
| STENTICO32 | 2005–06 | Multicentric/France | 359 | 100 | 0 | 0 | 0 |
| MUSICA33 | 2003–06 | Multicentric/Spain | 405 | 69 | 11 | 20 | 0 |
| AFCAS34 | 2008–10 | Multicentric/Europe | 914 | 74 | 8 | 18 | 0 |
| WARSTENT35 | 2008–10 | Multicentric/Italy | 401 | 85 | 5 | 10 | 0 |
| Sambola et al.36 | 2003–12 | Multicentric/Spain | 585 | 55 | 0 | 45 | 0 |
| Horie et al.37 | 2015–17 | Multicentric/Japan | 285 | 100 | 0 | 0 | 0 |
| CHUM AF STENT38 | 2010–19 | Multicentric/Canada | 561 | 44 | 8 | 47 | 32 |
| GRAPE AF39 | 2017–19 | Multicentric/Greece | 654 | 50 | 49 | 1 | 93 |
| MATADOR-PCI40 | 2018–19 | Multicentric/Italy | 588 | 65 | 9 | 26 | 62 |
| Author/acronym . | Years . | . | Patients (n) . | TAT (%) . | DAT (%) . | DAPT (%) . | DOAC (%) . |
|---|---|---|---|---|---|---|---|
| Saratoff et al.31 | 2002–07 | Monocenter/Germany | 515 | 59 | 0 | 41 | 0 |
| STENTICO32 | 2005–06 | Multicentric/France | 359 | 100 | 0 | 0 | 0 |
| MUSICA33 | 2003–06 | Multicentric/Spain | 405 | 69 | 11 | 20 | 0 |
| AFCAS34 | 2008–10 | Multicentric/Europe | 914 | 74 | 8 | 18 | 0 |
| WARSTENT35 | 2008–10 | Multicentric/Italy | 401 | 85 | 5 | 10 | 0 |
| Sambola et al.36 | 2003–12 | Multicentric/Spain | 585 | 55 | 0 | 45 | 0 |
| Horie et al.37 | 2015–17 | Multicentric/Japan | 285 | 100 | 0 | 0 | 0 |
| CHUM AF STENT38 | 2010–19 | Multicentric/Canada | 561 | 44 | 8 | 47 | 32 |
| GRAPE AF39 | 2017–19 | Multicentric/Greece | 654 | 50 | 49 | 1 | 93 |
| MATADOR-PCI40 | 2018–19 | Multicentric/Italy | 588 | 65 | 9 | 26 | 62 |
DAPT, dual antiplatelet therapy; DAT, dual antithrombotic therapy (anticoagulant + single antiplatelet); DOAC, direct anticoagulants; TAT, triple antithrombotic therapy (anticoagulant + dual antiplatelet therapy).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
